Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025

Nuvation Bio Inc.

2025-Q1 EPS reported -$0.16 revenue$3,084,000

Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.
Cash, equivalents and marketable securities $461.7M as of March 31, 2025.
FDA Priority Review for taletrectinib NDA on track; PDUFA goal date June 23, 2025.
Secured up to $250M non-dilutive financing from Sagard Healthcare; $150M royalty and $50M debt upon FDA approval.
Appointed Stephen Dang, Ph.D., as Senior Vice President, General Counsel in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.